Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury

Edwin Vázquez-Rosa, Michael R. Watson, James J. Sahn, Timothy R. Hodges, Rachel E. Schroeder, Coral J. Cintrón-Pérez, Min Kyoo Shin, Terry C. Yin, Josie L. Emery, Stephen F. Martin, Daniel J Liebl, Andrew A. Pieper

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Compounds targeting the sigma 2 receptor, which we recently cloned and showed to be identical with transmembrane protein 97 (σ2R/TMEM97), are broadly applicable therapeutic agents currently in clinical trials for imaging in breast cancer and for treatment of Alzheimer's disease and schizophrenia. These promising applications coupled with our previous observation that the σ2R/TMEM97 modulator SAS-0132 has neuroprotective attributes and improves cognition in wild-type mice suggests that modulating σ2R/TMEM97 may also have therapeutic benefits in other neurodegenerative conditions such as traumatic brain injury (TBI). Herein, we report that DKR-1677, a novel derivative of SAS-0132 with increased affinity and selectivity for σ2R/Tmem97 (Ki = 5.1 nM), is neuroprotective after blast-induced and controlled cortical impact (CCI) TBI in mice. Specifically, we discovered that treatment with DKR-1677 decreases axonal degeneration after blast-induced TBI and enhances survival of cortical neurons and oligodendrocytes after CCI injury. Furthermore, treatment with DKR-1677 preserves cognition in the Morris water maze after blast TBI. Our results support an increasingly broad role for σ2R/Tmem97 modulation in neuroprotection and suggest a new approach for treating patients suffering from TBI.

Original languageEnglish (US)
JournalACS Chemical Neuroscience
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Modulators
Brain
Cognition
Therapeutics
Oligodendroglia
Neurons
Schizophrenia
Alzheimer Disease
Modulation
sigma-2 receptor
Traumatic Brain Injury
Clinical Trials
Breast Neoplasms
Derivatives
Imaging techniques
Water
Wounds and Injuries
Proteins

Keywords

  • blast injury
  • controlled cortical impact injury
  • Neuroprotection
  • traumatic brain injury
  • σ2R/TMEM97

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Vázquez-Rosa, E., Watson, M. R., Sahn, J. J., Hodges, T. R., Schroeder, R. E., Cintrón-Pérez, C. J., ... Pieper, A. A. (Accepted/In press). Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.8b00543

Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury. / Vázquez-Rosa, Edwin; Watson, Michael R.; Sahn, James J.; Hodges, Timothy R.; Schroeder, Rachel E.; Cintrón-Pérez, Coral J.; Shin, Min Kyoo; Yin, Terry C.; Emery, Josie L.; Martin, Stephen F.; Liebl, Daniel J; Pieper, Andrew A.

In: ACS Chemical Neuroscience, 01.01.2018.

Research output: Contribution to journalArticle

Vázquez-Rosa, E, Watson, MR, Sahn, JJ, Hodges, TR, Schroeder, RE, Cintrón-Pérez, CJ, Shin, MK, Yin, TC, Emery, JL, Martin, SF, Liebl, DJ & Pieper, AA 2018, 'Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury', ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.8b00543
Vázquez-Rosa, Edwin ; Watson, Michael R. ; Sahn, James J. ; Hodges, Timothy R. ; Schroeder, Rachel E. ; Cintrón-Pérez, Coral J. ; Shin, Min Kyoo ; Yin, Terry C. ; Emery, Josie L. ; Martin, Stephen F. ; Liebl, Daniel J ; Pieper, Andrew A. / Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury. In: ACS Chemical Neuroscience. 2018.
@article{c455abf94d26475ebd301649f17fcb18,
title = "Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury",
abstract = "Compounds targeting the sigma 2 receptor, which we recently cloned and showed to be identical with transmembrane protein 97 (σ2R/TMEM97), are broadly applicable therapeutic agents currently in clinical trials for imaging in breast cancer and for treatment of Alzheimer's disease and schizophrenia. These promising applications coupled with our previous observation that the σ2R/TMEM97 modulator SAS-0132 has neuroprotective attributes and improves cognition in wild-type mice suggests that modulating σ2R/TMEM97 may also have therapeutic benefits in other neurodegenerative conditions such as traumatic brain injury (TBI). Herein, we report that DKR-1677, a novel derivative of SAS-0132 with increased affinity and selectivity for σ2R/Tmem97 (Ki = 5.1 nM), is neuroprotective after blast-induced and controlled cortical impact (CCI) TBI in mice. Specifically, we discovered that treatment with DKR-1677 decreases axonal degeneration after blast-induced TBI and enhances survival of cortical neurons and oligodendrocytes after CCI injury. Furthermore, treatment with DKR-1677 preserves cognition in the Morris water maze after blast TBI. Our results support an increasingly broad role for σ2R/Tmem97 modulation in neuroprotection and suggest a new approach for treating patients suffering from TBI.",
keywords = "blast injury, controlled cortical impact injury, Neuroprotection, traumatic brain injury, σ2R/TMEM97",
author = "Edwin V{\'a}zquez-Rosa and Watson, {Michael R.} and Sahn, {James J.} and Hodges, {Timothy R.} and Schroeder, {Rachel E.} and Cintr{\'o}n-P{\'e}rez, {Coral J.} and Shin, {Min Kyoo} and Yin, {Terry C.} and Emery, {Josie L.} and Martin, {Stephen F.} and Liebl, {Daniel J} and Pieper, {Andrew A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1021/acschemneuro.8b00543",
language = "English (US)",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury

AU - Vázquez-Rosa, Edwin

AU - Watson, Michael R.

AU - Sahn, James J.

AU - Hodges, Timothy R.

AU - Schroeder, Rachel E.

AU - Cintrón-Pérez, Coral J.

AU - Shin, Min Kyoo

AU - Yin, Terry C.

AU - Emery, Josie L.

AU - Martin, Stephen F.

AU - Liebl, Daniel J

AU - Pieper, Andrew A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Compounds targeting the sigma 2 receptor, which we recently cloned and showed to be identical with transmembrane protein 97 (σ2R/TMEM97), are broadly applicable therapeutic agents currently in clinical trials for imaging in breast cancer and for treatment of Alzheimer's disease and schizophrenia. These promising applications coupled with our previous observation that the σ2R/TMEM97 modulator SAS-0132 has neuroprotective attributes and improves cognition in wild-type mice suggests that modulating σ2R/TMEM97 may also have therapeutic benefits in other neurodegenerative conditions such as traumatic brain injury (TBI). Herein, we report that DKR-1677, a novel derivative of SAS-0132 with increased affinity and selectivity for σ2R/Tmem97 (Ki = 5.1 nM), is neuroprotective after blast-induced and controlled cortical impact (CCI) TBI in mice. Specifically, we discovered that treatment with DKR-1677 decreases axonal degeneration after blast-induced TBI and enhances survival of cortical neurons and oligodendrocytes after CCI injury. Furthermore, treatment with DKR-1677 preserves cognition in the Morris water maze after blast TBI. Our results support an increasingly broad role for σ2R/Tmem97 modulation in neuroprotection and suggest a new approach for treating patients suffering from TBI.

AB - Compounds targeting the sigma 2 receptor, which we recently cloned and showed to be identical with transmembrane protein 97 (σ2R/TMEM97), are broadly applicable therapeutic agents currently in clinical trials for imaging in breast cancer and for treatment of Alzheimer's disease and schizophrenia. These promising applications coupled with our previous observation that the σ2R/TMEM97 modulator SAS-0132 has neuroprotective attributes and improves cognition in wild-type mice suggests that modulating σ2R/TMEM97 may also have therapeutic benefits in other neurodegenerative conditions such as traumatic brain injury (TBI). Herein, we report that DKR-1677, a novel derivative of SAS-0132 with increased affinity and selectivity for σ2R/Tmem97 (Ki = 5.1 nM), is neuroprotective after blast-induced and controlled cortical impact (CCI) TBI in mice. Specifically, we discovered that treatment with DKR-1677 decreases axonal degeneration after blast-induced TBI and enhances survival of cortical neurons and oligodendrocytes after CCI injury. Furthermore, treatment with DKR-1677 preserves cognition in the Morris water maze after blast TBI. Our results support an increasingly broad role for σ2R/Tmem97 modulation in neuroprotection and suggest a new approach for treating patients suffering from TBI.

KW - blast injury

KW - controlled cortical impact injury

KW - Neuroprotection

KW - traumatic brain injury

KW - σ2R/TMEM97

UR - http://www.scopus.com/inward/record.url?scp=85058169078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058169078&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.8b00543

DO - 10.1021/acschemneuro.8b00543

M3 - Article

C2 - 30421909

AN - SCOPUS:85058169078

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

ER -